SCHEMBL716805

SCHEMBL716805

Cc1nc(N)nc(N[C@@H](C)c2cc3cccc(C)c3nc2N2CCNC(=O)C2)n1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.40
SOS1 Q07889 2/20 0.38
TSHR P16473 2/20 0.33
ALOX15 P16050 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KRAS P01116 1/20 0.33
IDH1 O75874 2/20 0.32
PRKCH P24723 1/20 0.32
PRKCE Q02156 1/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CLK1 P49759 1/20 0.32
PIK3R2 O00459 1/20 0.32
HRH4 Q9H3N8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717467 0.92 PIK3CD (0.41) PIK3CDSOS1TSHRALOX15CASP1
SCHEMBL713510 0.91 PIK3CD (0.38) PIK3CDSOS1KRASIDH1PRKCH
SCHEMBL713509 0.91 PIK3CD (0.38) PIK3CDSOS1KRASIDH1PRKCH
SCHEMBL718089 0.89 PIK3CD (0.42) PIK3CDSOS1IDH1
SCHEMBL718088 0.89 PIK3CD (0.42) PIK3CDSOS1IDH1
SCHEMBL715604 0.87 PIK3CD (0.47) PIK3CDSOS1TSHRALOX15CASP1
SCHEMBL717881 0.86 SOS1 (0.39) SOS1KRASIDH1PRKCHPRKCE
SCHEMBL717880 0.86 SOS1 (0.39) SOS1KRASIDH1PRKCHPRKCE
SCHEMBL714110 0.85 SOS1 (0.37) SOS1KRASIDH1PRKCHPRKCE
SCHEMBL714109 0.85 SOS1 (0.37) SOS1KRASIDH1PRKCHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885SOS1 1414/4885TSHR 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.